Jared Kaltwasser

The new analysis suggests that dementia screenings might also include kidney function estimation.

People who suffer from shift work sleep disorder face the highest risk of a car crash, although sleep apnea and insomnia also heighten a person’s risk.

Children with severe atopic dermatitis, in particular, were less likely than a control group to complete education at all levels, from basic compulsory education to postgraduate education.

A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral prostacyclin.

When patients had the option of using prescription digital therapeutics, their insurers and employers saved significant money in both direct and indirect medical costs, the 2 studies found.

Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.

A report using data from the DAPA-CKD study found that dapagliflozin would lead to more than $99 million in savings in a population matched to the trial’s inclusion criteria.

A small study, based on 4 family members with Fabry disease, affirms the importance of early enzyme replacement therapy.

About 90% of patients are diagnosed with rheumatoid arthritis in an outpatient setting, while the 10% diagnosed in an emergency department or as inpatients incur significantly higher health care costs.

In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation.

About 1 in 3 patients experienced adverse drug reactions in the 2 new safety studies, aligning with earlier reports.

All-cause graft failure in kidney transplant recipients with Fabry disease was about 30%, and improved when enzyme replacement therapy became available.

Despite concerns that patients with Fabry disease might be at heightened risk of severe symptoms from SARS-CoV-2, early data find that most patients experience mild or moderate symptoms.

Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.

Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).

In an unexpected finding, patients with psoriasis showed similar hand impairment to patients with psoriatic arthritis and rheumatoid arthritis.

A small pilot study could point the way to a new option for patients with B-cell acute lymphoblastic leukemia (B-ALL) who experience cytokine release syndrome (CRS) that cannot be cured with the standard therapy.

New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.

Most patients with bone metastases or multiple myeloma (MM) who are hospitalized with skeletal-related events require lengthy and costly follow-up care after they are discharged.

Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.

Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.

In roughly half of cases assessed, physicians underestimated a patients’ risk, according to multiparametric objective risk-assessment tools.

A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.

A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.

A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.

The research raises the possibility that the type of therapy used can increase the risk of tumor lysis syndrome from low to moderate in men with multiple myeloma (MM).

A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).

The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.

The new data provide hope that the therapy will prove effective for a patient group with limited options.

Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.